Short antimicrobial peptides and peptide scaffolds as promising antibacterial agents

Current Topics in Medicinal Chemistry

Volumn 16, Issue 11, 2016, Pages 1217-1230

  Domalaon, Ronald ^a   Zhanel, George G ^a   Schweizer, Frank ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Antibacterial peptidomimetics; Antibiotics; Antimicrobial peptides; Bacterial resistance; Cationic amphiphiles; Host defense peptides

Indexed keywords

4 AMINOPROLINE; ACYLDEPSIPEPTIDE; AMPHOPHILE; ARGININE; ARGININE RICH SHORT ANTIMICROBIAL PEPTIDE; BRILACIDIN; CECROPIN; DAPTOMYCIN; DEFENSIN; DIAMINOBUTYRIC ACID; EMPEDOPEPTIN; LACTOFERRIN 11 324; M 6; MAGAININ DERIVATIVE; MOLECULAR SCAFFOLD; MUREPAVADIN; OCTA 1; PEPTIDOMIMETIC AGENT; PLUSBACIN; POLYMYXIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; PROLINE; PROLINE RICH SHORT ANTIMICROBIAL PEPTIDE; RUTHENOCENE DERIVATIVE; STYLISIN; SUROTOMYCIN; TRIPROPEPTIN; TRYPTOPHAN; TRYPTOPHAN RICH SHORT ANTIMICROBIAL PEPTIDE; ULTRASHORT ANTIMICROBIAL PEPTIDE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; PEPTIDE;

AMINO ACID SEQUENCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BIOFILM; CHEMICAL MODIFICATION; DRUG SAFETY; DRUG SYNTHESIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HUMAN; HYDROPHOBICITY; KLEBSIELLA PNEUMONIAE; LD50; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STEREOCHEMISTRY; VANCOMYCIN RESISTANT ENTEROCOCCUS; BACTERIUM; CHEMISTRY; CONFORMATION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR CONFORMATION; PEPTIDES;

EID: 84961721905     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150915112459     Document Type: Article

References (136)

1. Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis., 2009, 48, 1-12.
2. Stanton, T.B. A call for antibiotic alternative research. Trends Microbiol., 2013, 21, 111-113.
3. Balsalobre, L.C.; Dropa, M.; Matté, M.H. An overview of antimicrobial resistance and its public health significance. Braz. J. Microbiol., 2014, 45, 1-5.
4. World Health Organization. Antimicrobial resistance: global report on surveillance. http://www.who.int/drugresistance/documents/surveillancereport/en/ (Accessed August 28, 2014).
5. Guilhelmelli, F.; Vilela, N.; Albuquerque, P.; Derengowski, L da S.; Silva-Pereira, I.; Kyaw, C.M. Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front. Microbiol., 2013, 4, 1-12.
6. Steiner, H.; Hultmark, D.; Engstrom, A.; Bennich, H.; Boman, H.G. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature, 1981, 292, 246-248.
7. Ganz, T.; Selsted M.E.; Szklarek, D.; Harwig, S.S.; Daher, K.; Bainton, D.F.; Lehrer, R.I. Defensins. Natural peptide antibiotics of human neutrophils. J. Clin. Invest., 1985, 76, 1427-1435.
8. Zasloff, M. Magainins, a class of antimicrobial peptides from Xenopus skin – isolation, characterization of 2 active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. U.S.A., 1987, 84, 5449-5453.
9. Mookherjee, N.; Hancock, R.E. Cationic host defence peptides: innate immune regulatory peptides as novel approach for treating infections. Cell. Mol. Life Sci., 2007, 64, 922-933.
10. Alba, A.; López-Abarrategui, C.; Otero-González, A.J. Host defense peptides: an alternative as antiinfective and immunomodulatory therapeutics. Biopolymers, 2012, 98, 251-267.
11. Mangoni, M.L. Host-defense peptides: from biology to therapeutic strategies. Cell. Mol. Life Sci., 2011, 68, 2157-2159.
12. Hilchie, A.L.; Wuerth, K.; Hancock, R.E. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat. Chem. Biol., 2013, 9, 761-768.
13. Lai, Y.; Gallo, R.L. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol., 2009, 30, 131-141.
14. Vandamme, D.; Landuyt, B.; Luyten, W.; Schoofs, L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell. Immunol., 2012, 280, 22-35.
15. van der Does, A.M.; Bergman, P.; Agerberth, B.; Lindbom, L. Induction of the human cathelicidin LL-37 as a novel treatment against bacterial infections. J. Leuokoc. Biol., 2012, 92, 735-742.
16. Schauber, J.; Iffland, K.; Frisch, S.; Kudlich, T.; Schmausser, B.; Eck, M.; Menzel, T.; Gostner, A.; Luhrs, H.; Scheppach, W. Histone- deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells. Mol. Immunol., 2004, 41, 847-854.
17. Wang, T.T.; Nestel, F.P.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavera-Mendoza, L.; Lin, R.; Hanrahan, J.W.; Mader, S.; White, J.H. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol., 2004, 173, 2909-2912.
18. Termen, S.; Tollin, M.; Rodriguez, E.; Sveinsdottir, S.H.; Johannesson, B.; Cederlund, A.; Sjovall, J.; Agerberth, B.; Gudmundsson, G.H. PU.1 and bacterial metabolites regulate the human gene CAMP encoding antimicrobial peptide LL-37 in colon epithelial cells. Mol. Immunol., 2008, 45, 3947-3955.
19. Nell, M.J.; Tjabringa, G.S.; Vonk, M.J.; Hiemstra, P.S.; Grote, J.J. Bacterial products increase expression of the human cathelicidin hCAP-18/LL-37 in cultured human sinus epithelial cells. FEMS Immunol. Med. Microbiol., 2004, 42, 225-231.
20. Ainsworth, G.C.; Brown, A.M.; Brownlee, G. Aerosporin, an antibiotic produced by Bacillus aerosporus Greer. Nature, 1947, 159, 263.
21. Sarkar, S.; DeSantis, E.R.; Kuper, J. Resurgence of colistin use. Am. J. Health Syst. Pharm., 2007, 64, 2462-2466.
22. Mostardeiro, M.M.; Pereira, C.A.; Marra, A.R.; Pestana, J.O.; Camargo, L.F. Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Antimicrob. Agents Chemother., 2013, 57, 1442-1446.
23. Averbuch, D.; Horwitz, E.; Strahilevitz, J.; Stepensky, P.; Goldschmidt, N.; Gatt, M.E.; Shapira, M.Y.; Resnick, I.B.; Engelhard, D. Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients. Infection, 2013, 41, 991-997.
24. Velkov, T.; Thompson, P.E.; Nation, R.L.; Li, J. Structure— activity relationships of polymyxin antibiotics. J. Med. Chem., 2010, 53, 1898-1916.
25. Velkov, T.; Roberts, K.D.; Nation, R.L.; Thompson, P.E.; Li, J. Pharmacology of polymyxins: new insights into an ‘old’ class of antibiotics., Future Microbiol., 2013, 8, 711-724.
26. Deris, Z.Z.; Akter, J.; Sivanesan, S.; Roberts, K.D.; Thompson, P.E.; Nation, R.L.; Li, J.; Velkov, T. A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity. J. Antibiot. (Tokyo), 2014, 67, 147-151.
27. McCoy, L.S.; Robert, K.D.; Nation, R.L.; Thompson, P.E.; Velkov, T.; Li, J.; Tor, Y. Polymyxins and analogues bind to ribosomal RNA and interfere with eukaryotic translation in vitro. Chembiochem, 2013, 14, 2083-2086.
28. Sampson, T.R.; Liu, X.; Schroeder, M.R.; Kraft, C.S.; Burd, E.M.; Weiss, D.S. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrob. Agents Chemother., 2012, 56, 5642-5649.
29. Cai, Y.; Cao, X.; Aballay, A. Whole-animal chemical screen identifies colistin as a new immunomodulator that targets conserved pathways. MBio, 2014, 5, e01235-14.
30. Takahashi, D.; Shukla, S.K.; Prakash, O.; Zhang, G. Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity. Biochimie, 2010, 92, 1236-1241.
31. Haney, E.F.; Hunter, H.N.; Matsuzaki, K.; Vogel, H.J. Solution NMR studies of amphibian antimicrobial peptides: Linking structure to function?. Biochim. Biophys. Acta, 2009, 1788, 1639-1655.
32. Wiradharma, N.; Khoe, U.; Hauser, C.A.; Seow, S.V.; Zhang, S.; Yang, Y.Y. Synthetic cationic amphiphilic α-helical peptides as antimicrobial agents. Biomaterials, 2011, 32, 2204-2212.
33. Jerala, R. Synthetic lipopeptides: a novel class of anti-infectives. Expert Opin. Investig. Drugs, 2007, 16, 1159-1169.
34. Pearson, A.L.; Metcalf, C.A., III; Li, J. (Cubist Pharmaceuticals, Inc.) Novel lipopeptide antibacterial agents for the treatment of Gram positive infections. US Patent 20100184649 A1, July 22, 2010.
35. Snydman, D.R.; Jacobus, N.V.; McDermott, L.A. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob. Agents Chemother., 2012, 56, 3448-3452.
36. Mascio, C.T.; Chesnel, L.; Thorne, G.; Silverman, J.A. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium. Antimicrob. Agents Chemother., 2014, 58, 3976-3982.
37. Beiras-Fernandez, A.; Vogt, F.; Sodian, R.; Weis, F. Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens. Infect. Drug Resist., 2010, 3, 95-101.
38. Humphries R.M.; Pollett, S.; Sakoulas, G. A current perspective on daptomycin for the clinical microbiologist. Clin. Microbiol. Rev., 2013, 26, 759-780.
39. Butler, M.S.; Blaskovich, M.A.; Cooper, M.A. Antibiotics in the clinical pipeline in 2013. J. Antibiot. (Tokyo), 2013, 66, 571-591.
40. Schweizer, F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur. J. Pharmacol., 2009, 625, 190-194.
41. Gaspar, D.; Veiga, A.S.; Castanho, M.A. From antimicrobial to anticancer peptides. A review. Front. Microbiol., 2013, 4, 1-16.
42. Nguyen, L.T.; Haney, E.F.; Vogel, H.J. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol., 2011, 29, 464-472.
43. Dennison, S.R.; Phoenix, D.A. Effect of cholesterol on the membrane interaction of Modelin-5 isoforms. Biochemistry, 2011, 50, 10898-10909.
44. McHernry, A.J.; Sciacca, M.F.; Bremder, J.R.; Ramamoorthy, A. Does cholesterol suppress the antimicrobial peptide induced disruption of lipid raft containing membranes?. Biochim. Biophys. Acta, 2012, 1818, 3019-3024.
45. Han, F.F.; Gao, Y.H.; Luan, C.; Xie, Y.G.; Liu, Y.F.; Wang, Y.Z. Comparing bacterial membrane interactions and antimicrobial activity of porcine lactoferricin-derived peptides. J. Dairy Sci., 2013, 96, 3471-3487.
46. Gee, M.L.; Burton, M.; Grevis-James, A.; Hossain, M.A.; McArthur, S.; Palombo, E.A.; Wade, J.D.; Clayton, A.H. Imaging the action of antimicrobial peptides on living bacterial cells. Sci. Rep., 2013, 3, 1557.
47. Matsuzaki, K.; Murase, O.; Fujii, N.; Miyajima, K. An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry, 1996, 35, 11361-11368.
48. Bierbaum, G.; Sahl, H.G. Induction of autolysis of staphylococci by the basic peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic enzymes. Arch. Microbiol., 1985, 141, 249-254.
49. Haney, E.F.; Petersen, A.P.; Lau, C.K.; Jing, W.; Storey, D.G.; Vogel, H.J. Mechanism of action of puroindoline derived tryptophan- rich antimicrobial peptides. Biochim. Biophys. Acta, 2013, 1828, 1802-1813.
50. Friedrich, C.L.; Rozek, A.; Patrzykat, A.; Hancock, R.E. Structure and mechanism of action of an indolicidin peptide derivative with improved activity against gram-positive bacteria. J. Biol. Chem., 2001, 276, 24015-24022.
51. Yeung, A.T.; Gellatly, S.L.; Hancock, R.E. Multifunctional cationic host defence peptides and their clinical applications. Cell. Mol. Life Sci., 2011, 68, 2161-2176.
52. Wang, G.; Li, X.; Wang, Z. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res., 2009, 37, D933-D937.
53. Chan, D.I.; Prenner, E.J.; Vogel, H.J. Tryptophan- and argininerich antimicrobial peptides: structures and mechanisms of action. Biochim. Biophys. Acta, 2006, 1758, 1184-1202.
54. Yau, W.M.; Wimley, W.C.; Gawrisch, K.; White S.H. The preference of tryptophan for membrane interfaces. Biochemistry, 1998, 37, 14713-14718.
55. Shepherd, C.M.; Vogel, H.J.; Tieleman, D.P. Interactions of the designed antimicrobial peptide MB21 and truncated dermaseptin S3 with lipid bilayers: molecular-dynamics simulation. Biochem. J., 2003, 370, 233-243.
56. Aliste, M.P.; MacCallum, J.L.; Tieleman, D.P. Molecular dynamics simulations of pentapeptides at interfaces: salt bridge and cation-pi interactions. Biochemistry, 2003, 42, 8976-8987.
57. Kachel, K.; Asuncion-Punzalan, E.; London, E. Anchoring of tryptophan and tyrosine analogs at the hydrocarbon-polar boundary in model membrane vesicles: parallax analysis of fluorescence quenching induced by nitroxide-labeled phospholipids. Biochemistry, 1995, 34, 15475-15479.
58. Dougherty, D.A. Cationi-pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp. Science, 1996, 271, 163-168.
59. Minoux, H.; Chipot, C. Cation-π interactions in proteins: can simple models provide an accurate description? J. Am. Chem. Soc., 1999, 121, 10366-10372.
60. Mitchell, J.B.; Nandi, C.L.; McDonald, I.K.; Thornton, J.M.; Price, S.L. Amino/aromatic interactions in proteins: is the evidence stacked against hydrogen bonding? J. Mol. Biol., 1994, 239, 315-331.
61. Jing, W.; Demcoe, A.R.; Vogel, H.J. Conformation of bactericidal domain of puroindoline a: structure and mechanism of action of a 13-residue antimicrobial peptide. J. Bacteriol., 2003, 185, 4938-4947.
62. Vogel, H.J.; Schibli, D.J.; Jing, W.; Lohmeier-Vogel, E.M.; Epand, R.F.; Epand, R.M. Towards a structure-function analysis of bovine lactoferricin and related tryptophan- and arginine- containing peptides. Biochem. Cell. Biol., 2002, 80, 49-63.
63. Bellamy, W.; Takase, M.; Yamauchi, K.; Wakabayashi, H.; Kawase, K.; Tomita, M. Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta, 1992, 1121, 130-136.
64. Zweytick, D.; Deutsch, G.; Andra, J.; Blondelle, S.E.; Vollmer, E.; Jerala, R.; Lohner, K. Studies on the lactoferricin-derived Escherichia coli membrane-active peptides reveal differences in the mechanism of N-acylated versus nonacylated peptides. J. Biol. Chem., 2011, 286, 21266-21276.
65. Zweytick, D.; Tumer, S.; Blondelle, S.E.; Lohner, K. Membrane curvature stress and antibacterial activity of lactoferricin derivatives. Biochem. Biophys. Res. Commun., 2008, 369, 395-400.
66. Yang, N.; Strøm, M.B.; Mekonnen, S.M; Svendsen, J.S.; Rekdal, O. The effects of shortening lactoferrin dereived peptides against tumour cells, bacteria and normal human cells. J. Pept. Sci., 2004, 10, 37-46.
67. Blondelle, S.E.; Pérez-Payá, E.; Houghten R.A. Synthetic combinatorial libraries: novel discovery strategy for identification of antimicrobial agents. Antimicrob. Agents Chemother., 1996, 40, 1067-1071.
68. Strøm, M.B.; Rekdal, O.; Svendsen J.S. Antimicrobial activity of short arginine- and tryptophan-rich peptides. J. Pept. Sci., 2002, 8, 431-437.
69. Houghten, R.A.; Pinilla, C.; Blondelle, S.E.; Appel, J.R.; Dooley, C.T.; Cuervo, J.H. Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature, 1991, 354, 84-86.
70. Wei, S.Y.; Wu, J.M.; Kuo, Y.Y.; Chen, H.L.; Yip, B.S.; Tzeng, S.R.; Cheng, J.W. Solution structure of a novel tryptophan-rich peptide with bidirectional antimicrobial activity. J. Bacteriol., 2006, 188, 328-334.
71. Strøm, M.B.; Haug, B.E.; Skar, M.L.; Stensen, W.; Stiberg, T.; Svendsen, J.S. The pharmacophore of short cationic antibacterial peptides. J. Med. Chem., 2003, 46, 1567-1570.
72. Lui, Z.; Brady, A.; Young, A.; Rasimick, B.; Chen, K.; Zhou, C.; Kallenbach, N.R. Length effects in antimicrobial peptides of the (RW)n series. Antimicrob. Agents Chemother., 2007, 51, 597-603.
73. Wenzel, M.; Chiriac, A.I.; Otto, A.; Zweytick, D.; May, C.; Schumacher, C.; Gust, R.; Albada, H.B.; Penkova, M.; Kramer, U.; Erdmann, R.; Metzler-Nolte, N.; Straus, S.K.; Bremer, E.; Beched, D.; Brotz-Oesterhelt, H.; Sahl, H.G.; Bandow, J.E. Small cationic antimicrobial peptides delocalize peripheral membrane proteins. Proc. Natl. Acad. Sci. U.S.A., 2014, 111, E1409-E1418.
74. Albada, H.B.; Chiriac, A.I.; Wenzel, M.; Penkova, M.; Bandow, J.E.; Sahl, H.G.; Metzler-Nolte, N. Modulating the activity of short arginine-tryptophan containing antibacterial peptides with Nterminal metallocenoyl groups. Beilstein J. Org. Chem., 2012, 8, 1753-1764.
75. Albada, H.B.; Prochnow, P.; Bobersky, S.; Langklotz, S.; Schriek, P.; Bandow, J.E.; Metzler-Nolte, N. Tuning the activity of a short arg-trp antimicrobial peptide by lipidation of a C- or N-terminal lysine side-chain. ACS Med. Chem. Lett., 2012, 3, 980-984.
76. Albada, H.B.; Prochnow, P.; Bobersky, S.; Langklotz, S.; Bandow, J.E.; Metzler-Nolte, N. Short antibacterial peptides with significantly reduced hemolytic activity can be identified by a systematid L-to-D exchance scan of their amino acid residues. ACS Comb. Sci., 2013, 15, 585-592.
77. Saravanan, R.; Li, X.; Lim, K.; Mohanram, H.; Peng, L.; Mishra, B.; Basu, A.; Lee, J.M.; Bhattacharjya, S.; Leong, S.S. Design of short membrane selective antimicrobial peptides containing tryptophan and arginine residues for improved activity, salt-resistance, and biocompatibility. Biotechnol. Bioeng., 2014, 111, 37-49.
78. Rink, R.; Arkema-Meter, A.; Baudoin, I.; Post, E.; Kuipers, A.; Nelemans, S.A.; Akanbi, M.H.; Moll, G.N. To protect peptide pharmaceuticals against peptidases. J. Pharmacol. Toxicol. Methods, 2010, 61, 210-218.
79. Fang, Y.; Zhong, W.; Wang, Y.; Xun, T.; Lin, D.; Liu, W.; Wang, J.; Lv, L.; Liu, S.; He, J. Tuning the antimicrobial pharmacophore to enable discovery of short lipopeptides with multiple modes of action. Eur. J. Med. Chem., 2014, 18, 36-44.
80. Wessolowski, A.; Bienert, M.; Dathe, M. Antimicrobial activity of arginine- and tryptophan-rich hexapeptides: the effects of aromatic clusters, D-amino acid substitution and cyclization. J. Pept. Res., 2004, 64, 159-169.
81. Scocchi, M.; Tossi, A.; Gennaro, R. Proline-rich antimicrobial peptides: converging to a non-lytic mechanism of action. Cell. Mol. Life Sci., 2011, 68, 2317-2330.
82. Podda, E.; Benincasa, M.; Pacor, S.; Micali, F.; Mattiuzzo, M.; Gennaro, R.; Scocchi, M. Dual mode of action of Bac7, a prolinerich antibacterial peptide. Biochim. Biophys. Acta, 2006, 1760, 1732-1740.
83. Casteels, P.; Tempst, P. Apidaecin-type peptide antibiotics function through a non-poreforming mechanism involving stereospecificity. Biochem. Biophys. Res. Commun., 1994, 199, 339-345.
84. Otvos, L. Jr. The short proline-rich antibacterial peptide family. Cell. Mol. Life Sci., 2002, 59, 1138-1150.
85. Markossian, K.A.; Zamyatnin, A.A.; Kurganov, B.I. Antibacterial proline-rich oligopeptides and their target proteins. Biochemistry (Mosc.), 2004, 69, 1082-1091.
86. Konishi, M.; Sugawara, K.; Hanada, M.; Tomita, K.; Tomatsu, K.; Miyaki, T.; Kawaguchi, H.; Buck, R.E.; More, C.; Rossomano, V.Z. Empedopeptin (BMY-28117), a new depsipeptide antibiotic. I. Production, isolation and properties. J. Antibiot. (Tokyo), 1984, 37, 949-957.
87. Muller, A.; Munch, D.; Schmidt, Y.; Reder-Christ, K.; Schiffer, G.; Bendas, G.; Gross, H.; Sahl, H.G.; Schneider, T.; Brotz-Oesterhelt, H. Lipodepsipeptide empedopeptin inhibits cell wall biosynthesis through Ca2+-dependent complex formation with peptidoglycan precursors. J. Biol. Chem., 2012, 287, 20270-20280.
88. Hashizume, H.; Igarashi, M.; Hattori, S.; Hori, M.; Hamada, M.; Takeuchi, T. Tripropeptins, novel antimicrobial agents produced by Lysobacter sp. I. Taxonomy, isolation and biological activities. J. Antibiot., (Tokyo), 2001, 54, 1054-1059.
89. Hashizume, H.; Hattori, S.; Igarashi, M.; Akamatsu, Y. Tripropeptin E, a new tripropeptin group antibiotic produced by Lysobacter sp. BMK333-48F3. J. Antibiot. (Tokyo), 2004, 57, 394-399.
90. Hashizume, H.; Igarashi, M.; Sawa, R.; Adachi, H.; Nishimura, Y.; Akamatsu, Y. A new type of tripropeptin with anteiso-branched chain fatty acid from Lysobacter sp. BMK333-48F3. J. Antibiot. (Tokyo), 2008, 61, 577-582.
91. Shoji, J.; Hinoo, H.; Katayama, T.; Matsumoto, K.; Tanimoto, T.; Hattori, T.; Higashiyama, I.; Miwa, H.; Motokawa, K.; Yoshida, T. Isolation and characterization of new peptide antibiotics, plusbacins A1-A4 and B1-B4. J. Antibiot. (Tokyo), 1992, 45, 817-823.
92. Maki, H.; Miura, K.; Yamano, Y. Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother., 2001, 45, 1823-1827.
93. Li, D.H.; Chung, Y.S.; Gloyd, M.; Joseph, E.; Ghirlando, R.; Wright, G.D.; Cheng, Y.Q.; Maurizi, M.R.; Guarne, A.; Ortega, J. Acyldepsipeptide antibiotics induce the formation of a structured axial channel in ClpP: A model for the ClpX/ClpA-bound state of ClpP. Chem. Biol., 2010, 17, 959-969.
94. Conlon, B.P.; Nakayasu, E.S.; Fleck, L.E.; LaFleur, M.D.; Isabella, V.M.; Coleman, K.; Leonard, S.N.; Smith, R.D.; Adkins, J.N.; Lewis, K. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature, 2013, 503, 365-370.
95. Michel, K.H.; Kastner, R.E. A54556 antibiotics and process for production thereof. US Patent 4492650 A, January 8, 1985.
96. Osada, H.; Yano, T.; Koshino, H.; Isono, K. Enopeptin A, a novel depsipeptide antibiotic with anti-bacteriophage activity. J. Antiobiot. (Tokyo), 1991, 44, 1463-1466.
97. Hinzen, B.; Raddatz, S.; Paulsen, H.; Lampe, T.; Schumacher, A.; Häbich, D.; Hellwig, V.; Benet-Buchholz, J.; Endermann, R.; Labischinski, H.; Brötz-Oesterhelt, H. Medicinal chemistry optimization of acyldepsipeptides of the enopeptin class antibiotics. ChemMedChem, 2006, 1, 689-693.
98. Socha, A.M.; Tan, N.Y.; LaPlante, K.L.; Sello, J.K. Diversityoriented synthesis of cyclic acyldepsipeptides leads to the discovery of a potent antibacterial agent. Bioorg. Med. Chem., 2010, 18, 7193-7202.
99. Carney, D.W.; Schmitz, K.R.; Truong, J.V.; Sauer, R.T.; Sello, J.K. Restriction of the conformational dynamics of the cyclic acyldepsipeptide antibiotics improves their antibacterial activity. J. Am. Chem. Soc., 2014, 136, 1922-1929.
100. Mohammed, R.; Peng, J.; Kelly, M.; Hamann, M.T. Cyclic heptapeptides from the Jamaican sponge Stylissa caribica. J. Nat. Prod., 2006, 69, 1739-1744.
101. Dahiya, R.; Kumar, A.; Gupta, R. Synthesis, cytotoxic and antimicrobial screening of a proline-rich cyclopolypeptide. Chem. Pharm. Bull. (Tokyo), 2009, 57, 214-217.
102. Dahiya, R.; Gautam, H. Total synthesis and antimicrobial activity of a natural cycloheptapeptide of marine origin. Mar. Drugs, 2010, 8, 2384-2394.
103. Sugawara, K.; Numata, K.; Konishi, M.; Kawaguchi H. Empedopeptin (BMY-28117), a new depsipeptide antibiotic. II. Structure determination. J. Antibiot. (Tokyo), 1984, 37, 958-964.
104. Hashizume, H.; Hirosawa, S.; Sawa, R.; Muraoka, Y.; Ikeda, D.; Naganawa, H.; Igarashi, M. Tripropeptins, novel antimicrobial agents produced by Lysobacter sp. II. Structure elucidation. J. Antiobiot. (Tokyo), 2004, 57, 52-58.
105. Shoji, J.; Hinoo, H.; Katayama, T.; Nakagawa, Y.; Ikenishi, Y.; Iwatani, K.; Yoshida, T. Structures of new peptide antibiotics, plusbacins A1-A4 and B1-B4. J. Antibiot. (Tokyo), 1992, 45, 824-831.
106. Kumar, S.N.; Mohandas, C.; Nambisan, B. Purification, structural elucidation and bioactivity of tryptophan containing diketopiperazines, from Comamonas testosterone associated with a rhabditid entomopathogenic nematode against major humanpathogenic bacteria. Peptides, 2014, 53, 48-58.
107. Roy, S.; Das, P.K. Antibacterial hydrogels of amino acid-based cationic amphiphiles. Biotechnol. Bioeng., 2008, 100, 756-764.
108. Mitra, R.N.; Shome, A.; Paul, P.; Das, P.K. Antimicrobial activity, biocompatibility and hydrogelation ability of dipeptide-based amphiphiles. Org. Biomol. Chem., 2009, 7, 94-102.
109. Makovitzki, A.; Avrahami, D.; Shai, Y. Ultrashort antibacterial and antifungal lipopeptides. Proc. Natl. Acad. U.S.A., 2006, 103, 15997-16002.
110. Findlay, B.; Mookherjee, N.; Schweizer, F. Ultrashort cationic lipopeptides and lipopeptoids selectively induced cytokine production in macrophages. PLoS One, 2013, 8, e54280.
111. Serrano, G.N.; Zhanel, G.G.; Schweizer, F. Antibacterial activity of ultrashort cationic lipo-beta-peptides. Antimicrob. Agents Chemother., 2009, 53, 2214-2217.
112. Findlay, B.; Zhanel, G.G.; Schweizer, F. Investigating the antimicrobial peptide ‘window of activity’ using cationic lipopeptides with hydrocarbon and fluorinated tails. Int. J. Antimicrob. Agents, 2012, 40, 36-42.
113. Domalaon, R.; Yang, X.; O’Neil, J.; Zhanel, G.G.; Mookherjee, N.; Schweizer F. Structure-activity relationships in ultrashort cationic lipopeptides: the effects of amino acid ring constraint on antibacterial activity. Amino Acids, 2014, 46, 2517-2530.
114. Godballe, T.; Nilsson, L.L.; Petersen, P.D.; Jenssen, H. Antimicrobial β-peptides and α-peptoids. Chem. Biol. Drug Res., 2011, 77, 107-116.
115. Giuliani, A.; Rinaldi, A.C. Beyond natural antimicrobial peptides: multimeric peptides and other peptidomimetic approaches. Cell. Mol. Life Sci., 2011, 68, 2255-2266.
116. Herzog, I.M.; Fridman, M. Design and synthesis of membranetargeting antibiotics: from peptides- to aminosugar-based antimicrobial cationic amphiphiles. Med. Chem. Commun., 2014, 5, 1014-1026.
117. Obrecht, D.; Robinson, J.A.; Bernardini, F.; Bisang, C.; DeMarco, S.J.: Moehle, K.; Gombert, F.O. Recent progress in the discovery of macrocyclic compounds as potential anti-infective therapeutics. Curr. Med. Chem., 2009, 16, 42-65.
118. Jamieson, A.G.; Boutard, N.; Sabatino, D.; Lubell, W.D. Peptide scanning for studying structure-activity relationships in drug discovery. Chem. Biol. Drug Des., 2013, 81, 148-165.
119. Niu, Y.; Wu, H.; Li, Y.; Hu, Y.; Padhee, S.; Li, Q.; Cao, C.; Cai, J. AApeptides as a new class of antimicrobial agents. Org. Biomol. Chem., 2013, 11, 4283-4290.
120. Méndez-Samperio, P. Peptidomimetics as a new generation of antimicrobial agents: current progress. Infect. Drug Resist., 2014, 7, 229-237.
121. Findlay, B.; Zhanel, G.G.; Schweizer, F. Cationic amphiphilies, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold. Antimicrob. Agents Chemother., 2010, 54, 4049-4058.
122. Jahnsen, R.D.; Frimodt-Møller, N.; Franzyk, H. Antimicrobial activity of peptidomimetics against multidrug-resistant Escherichia coli: a comparative study of different backbones. J. Med. Chem., 2012, 55, 7253-7261.
123. Jahnsen, R.D.; Haney, E.F.; Franzyk, H.; Hancock, R.E. Characterization of a proteolytically stable multifunctional host defense peptidomimetic. Chem. Biol., 2013, 20, 1286-1295.
124. Ghosh, C.; Manjunath, G.B.; Akkapeddi, P.; Yarlagadda, V.; Hogue, J.; Uppu, D.S.; Konai, M.M.; Haldar, J. Small molecular antibacterial peptoid mimics: the simpler the better!. J. Med. Chem., 2014, 57, 1428-1436.
125. Babii, O.; Afonin, S.; Berditsch, M.; Reiβer, S.; Mykhailiuk, P.K.; Kubyshkin, V.S.; Steinbrecher, T.; Ulrich, A.S.; Komarov, I.V. Controlling biological activity with light: diarylethene-containing cyclic peptidomimetics. Angew. Chem. Int. Ed. Engl., 2014, 53, 3392-3395.
126. Haug, B.E.; Stensen, W.; Stiberg, T.; Svendsen, J.S. Bulky nonproteinogenic amino acids permit the design of very small and effective cationic antibacterial peptides. J. Med. Chem., 2004, 47, 4159-4162.
127. Haug, B.E.; Stensen, W.; Svendsen, J.S. Application of the Suzuki- Miyaura cross-coupling to increase antimicrobial potency generates promising novel antibacterials. Bioorg. Med. Chem. Lett., 2007, 17, 2361-2364.
128. Haug, B.E.; Stensen, W.; Kalaaji, M.; Rekdal, O.; Svendsen, J.S. Synthetic antimicrobial peptidomimetics with therapeutic potention. J. Med. Chem., 2008, 51, 4306-4314.
129. Saravolatz, L.D.; Pawlak, J.; Johnson, L.; Bonilla, H.; Saravolatz L.D. 2nd.; Fakih, M.G.; Fugelli, A.; Olsen, W.M. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillinresistant, vancomycin-intermediate, vancomycin-resistant, daptomycin- nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus. Antimicrob. Agents Chemother., 2012, 56, 4478-4482.
130. Isaksson, J.; Brandsdal, B.O.; Enggvist, M.; Flaten, G.E.; Svendsen, J.S.; Stensen, W. A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J. Med. Chem., 2011, 54, 5786-5795.
131. Tew, G.N.; Liu, D.; Chen, B.; Doerksen, R.J.; Kaplan, J.; Carroll, P.J.; Klein, M.L.; DeGrado, W.F. De novo design of biomimetic antimicrobial polymers. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 5110-5114.
132. Liu, D.; Choi, S.; Chen, B.; Doerksen, R.J.; Clements, D.J.; Winkler, J.D.; Klein, M.L.; DeGrado, W.F. Nontoxic membrane-active antimicrobial arylamide oligomers. Angew. Chem. Int. Ed. Engl., 2004, 43, 1158-1162.
133. Choi, S.; Isaacs, S.; Clements, D.; Liu, D.; Kim, H.; Scott, R.W.; Winkler, J.D.; DeGrado, W.F. De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers. Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 6968-6973.
134. Mensa, B.; Howell, G.L.; Scott, R.; De Grado, W.F. Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob. Agents Chemother., 2014, 58, 5136-5145.
135. Robinson, J.A.; Demarco, S.; Gombert, F.; Moehle, K.; Obrecht, D. The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov. Today, 2008, 13, 944-951.
136. Srinivas, N.; Jetter, P.; Ueberbacher, B.J.; Werneburg, M.; Zerbe, K.; Steinmann, J.; Van der Meijden, B.; Bernardini, F.; Lederer, A.; Dias, R.L.; Misson, P.E.; Henze, H.; Zumbrunn, J.; Gombert, F.O.; Obrecht, D.; Hunziker, P.; Schauer, S.; Ziegler, U.; Käch, A.; Eberl, L.; Riedel, K.; DeMarco, S.J.; Robinson, J.A. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science, 2010, 327, 1010-1013